ArticleInternational journal of nanomedicine2020
Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Meta-analysis of integrated ChIP-seq and transcriptome data revealed genomic regions affected by estrogen receptor alpha in breast cancer.BMC medical genomics · 2023Pooled it
- Biogenic Zinc Oxide Nanoparticles for Skin Disorders: Mechanistic Insights, Translational Challenges, and Future Prospects.Biological trace element research · 2026Review
- Laser-based assessment of nanoparticle effects on RBC aggregation: an in vitro study.Biomedical optics express · 2026Article
- Understanding the Molecular Toxicity of Metal-Based Nanoparticles Through Nanotoxicomics.International journal of nanomedicine · 2025Review
- Article
- iSMOD: an integrative browser for image-based single-cell multi-omics data.Nucleic acids research · 2023Article
- Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia.ADMET & DMPK · 2023Review
- Apoptotic pathway protein expression variance in metal oxide and quantum dot treated HeLa cells.microPublication biology · 2023Article
- In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.Scientific reports · 2022Article
- Current Research on Zinc Oxide Nanoparticles: Synthesis, Characterization, and Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Investigating the impact of RNA integrity variation on the transcriptome of human leukemic cells.3 Biotech · 2022Article
- A New Look at the Effects of Engineered ZnO and TiONanomaterials (Basel, Switzerland) · 2022Review
- Anticancer effect of zinc oxide nanoparticles prepared by varying entry time of ion carriers against A431 skin cancer cellsFrontiers in chemistry · 2022Article
- Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma.International journal of nanomedicine · 2022Article
- A stepwise-targeting strategy for the treatment of cerebral ischemic stroke.Journal of nanobiotechnology · 2021Article
- Targeting Engineered Nanoparticles for Breast Cancer Therapy.Pharmaceutics · 2021Review
- Analysis of Nanotoxicity with Integrated Omics and Mechanobiology.Nanomaterials (Basel, Switzerland) · 2021Review
- Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway.Saudi journal of biological sciences · 2021Article
- Tumor Microenvironment Responsive Pepper Mild Mottle Virus-Based Nanotubes for Targeted Delivery and Controlled Release of Paclitaxel.Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionZinc oxide nanoparticles (ZnO NPs) have recently attracted attention as potential anti-cancer agents. To the best of our knowledge, the toxicity of ZnO NPs against human chronic myeloid leukemia cells (K562 cell line) has not been studied using transcriptomics approach.
objectiveThe goals of this study were to evaluate the capability of ZnO NPs to induce apoptosis in human chronic myeloid leukemia cells (K562 cells) and to investigate the putative mechanisms of action.
methodsWe used viability assay and flowcytometry coupled with Annexin V-FITC and propidium iodide to investigate the toxicity of ZnO NPs on K562 cells and normal peripheral blood mononuclear cells. Next we utilized a DNA microarray-based transcriptomics approach to characterize the ZnO NPs-induced changes in the transcriptome of K562 cells.
resultsZnO NPs exerted a selective toxicity (mainly by apoptosis) on the leukemic cells (
conclusionTaken together, our findings support the earlier studies that reported anti-cancer activity of ZnO NPs and revealed possible molecular mechanisms employed by ZnO NPs to induce apoptosis in K562 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.